Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Metronomic capecitabine
DRUG
2 trials
Sponsors
Binghe Xu
, Zhejiang University
Conditions
Breast Diseases
Breast Neoplasms
Metastatic Pancreatic Carcinoma
Neoplasm Metastasis
Neoplasms by Site
Skin Diseases
Phase 2
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
Not yet recruiting
NCT06759090
Zhejiang University
Metastatic Pancreatic Carcinoma
Start: 2025-01-15
End: 2028-06-15
Target: 43
Updated: 2025-01-06
Phase 3
Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC
NCT01917279
Binghe Xu
Breast Diseases, Breast Neoplasms, Neoplasm Metastasis +2
Start: 2013-10-31
End: 2021-07-31
Target: 280
Updated: 2020-07-23
Related Papers
Genomic landscape of circulating tumor DNA in HER2-low metastatic breast cancer.
2024-12-09
4 citations
The molecular tumor burden index as a response evaluation criterion in breast cancer
Signal Transduction and Targeted Therapy
2021-07-07
58 citations
Analysis of circulating tumor DNA to monitor metastatic breast cancer patients treated with first-line chemotherapy (CAMELLIA study).
Journal of Clinical Oncology
2019-05-20
The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first‐line chemotherapy of HER2‐negative metastatic breast cancer
Cancer Communications
2019-01-03
113 citations
Correlation of circulating tumor cell phenotypes based on epithelial-mesenchymal transition with prognosis in first-line chemotherapy of HER2-negative metastatic breast cancer.
Journal of Clinical Oncology
2018-05-20
1 citations